Entrada Therapeutics Inc (TRDA)
17.74
+0.14
(+0.82%)
USD |
NASDAQ |
Nov 04, 16:00
17.76
+0.01
(+0.06%)
After-Hours: 20:00
Entrada Therapeutics PS Ratio: 2.566 for Nov. 4, 2024
PS Ratio Chart
Historical PS Ratio Data
| Date | Value |
|---|---|
| November 01, 2024 | 2.545 |
| October 31, 2024 | 2.478 |
| October 30, 2024 | 2.491 |
| October 29, 2024 | 2.498 |
| October 28, 2024 | 2.511 |
| October 25, 2024 | 2.456 |
| October 24, 2024 | 2.435 |
| October 23, 2024 | 2.454 |
| October 22, 2024 | 2.477 |
| October 21, 2024 | 2.504 |
| October 18, 2024 | 2.521 |
| October 17, 2024 | 2.549 |
| October 16, 2024 | 2.553 |
| October 15, 2024 | 2.534 |
| October 14, 2024 | 2.578 |
| October 11, 2024 | 2.426 |
| October 10, 2024 | 2.286 |
| October 09, 2024 | 2.338 |
| October 08, 2024 | 2.370 |
| October 07, 2024 | 2.391 |
| October 04, 2024 | 2.468 |
| October 03, 2024 | 2.377 |
| October 02, 2024 | 2.355 |
| October 01, 2024 | 2.313 |
| September 30, 2024 | 2.310 |
| Date | Value |
|---|---|
| September 27, 2024 | 2.378 |
| September 26, 2024 | 2.28 |
| September 25, 2024 | 2.176 |
| September 24, 2024 | 2.226 |
| September 23, 2024 | 2.106 |
| September 20, 2024 | 2.122 |
| September 19, 2024 | 2.169 |
| September 18, 2024 | 1.974 |
| September 17, 2024 | 2.047 |
| September 16, 2024 | 2.104 |
| September 13, 2024 | 2.169 |
| September 12, 2024 | 2.148 |
| September 11, 2024 | 2.148 |
| September 10, 2024 | 2.128 |
| September 09, 2024 | 2.173 |
| September 06, 2024 | 2.140 |
| September 05, 2024 | 2.225 |
| September 04, 2024 | 2.226 |
| September 03, 2024 | 2.263 |
| August 30, 2024 | 2.559 |
| August 29, 2024 | 2.530 |
| August 28, 2024 | 2.360 |
| August 27, 2024 | 2.414 |
| August 26, 2024 | 2.445 |
| August 23, 2024 | 2.388 |
Price to Sales Ratio Definition
The Price to Sales Ratio (PS Ratio) is calculated by taking the stock price / revenue per share (ttm). This metric is considered a valuation metric that confirms whether the sales of a company justifies the stock price. There isn't necesarily an optimum PS ratio, since different industries will have different ranges of PS Ratios. Because of this, PS Ratio is great to evaluate from a relative standpoint with other similar companies. PS Ratio might also be a handy metric for companies that are not profitable yet, since they might be valued moreso by their overall sales and potential of becoming profitable in the future.
PS Ratio Range, Past 5 Years
1.974
Minimum
Sep 18 2024
4.404
Maximum
Jan 09 2024
2.902
Average
2.792
Median
PS Ratio Benchmarks
| Fulcrum Therapeutics Inc | -- |
| Sarepta Therapeutics Inc | 7.992 |
| Catalyst Pharmaceuticals Inc | 5.861 |
| Vertex Pharmaceuticals Inc | 11.91 |
| Regenxbio Inc | 4.538 |
PS Ratio Related Metrics
| PE Ratio | 5.995 |
| Price to Book Value | 1.535 |
| Price | 17.74 |
| Earnings Yield | 16.68% |
| Market Cap | 660.11M |
| Operating PE Ratio | 6.572 |
| Normalized PE Ratio | 5.995 |